memo inOncology Special Issue ESMO 2017 report – now available!
PUBLISHED: 2017-12-08   1066 total views, 1 today

The 2017 ESMO report contains the latest updates in lung cancer regarding clinical management and cancer research that were presented at the European Society for Medical Oncology (ESMO) 2017 annual meeting, that took place in Madrid, Spain from September 8th–12th, 2017.

Highlights include the latest clinical trial results for the PD-L1 inhibitors atezolizumab and durvalumab, new data for the PD-1 inhibitor nivolumab and the toll-like receptor 9 agonist lefitolimod; a discussion of the optimal succession oftargeted agents across several treatment lines for both EGFR and ALK positive disease; positive data for combined dabrafenib/trametinib therapy for BRAF-positive lung cancer patients; and lots more.

The memo Special Issue report is produced by Springer, as a supplement of memo (the Magazine of European Medical Oncology), and sponsored by Boehringer Ingelheim  with an unrestricted educational grant. For more information on the memo inOncology Special Issue series, and for free access to all previous editions, visit the memo-inOncology website.

 

Download the full report (English)

Download the full report (Chinese)


Copyright © 1998 - 2018 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us

EMAIL:office@csco.org.cn

international@csco.org.cn

Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)